Celecoxib

Name: Celecoxib
Brand: Selleck Chemicals
SKU: S1261
Rating: 5 (66 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

66 publications

CAS No. 169590-42-5

Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Selleck's Celecoxib has been cited by 66 publications

Int J Mol Sci, 2021, 22(3)1194

PubMed: 33530480 ( click the link to review the publication )

J Clin Invest, 2020, 26;132417

PubMed: 32452837 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6299

PubMed: 33288764 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6339

PubMed: 33311482 ( click the link to review the publication )

Cell Death Differ, 2020, 20

PubMed: 32433558 ( click the link to review the publication )

Nanotoxicology, 2020, 14(2):162-180

PubMed: 31703536 ( click the link to review the publication )

Cells, 2020, 14;9(5):E1222

PubMed: 32423044 ( click the link to review the publication )

Aging (Albany NY), 2020, 12

PubMed: 33180744 ( click the link to review the publication )

Neoplasia, 2020, 22(11):576-589

PubMed: 32980776 ( click the link to review the publication )

J Inflamm Res, 2020, 13:1043-1055

PubMed: 33293848 ( click the link to review the publication )

J Clin Periodontol, 2020, 10.1111/jcpe.13283

PubMed: 32160330 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Brain Res, 2020, 20;1740:146846

PubMed: 32325074 ( click the link to review the publication )

AAPS PharmSciTech, 2020, 17;21(5):135

PubMed: 32419073 ( click the link to review the publication )

Biol Open, 2020, 9(11)bio053447

PubMed: 33148606 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):626

PubMed: 32796811 ( click the link to review the publication )

Cell Death Dis, 2020, 11(3):172

PubMed: 32139667 ( click the link to review the publication )

Osteoarthritis Cartilage, 2020, 28(4):502-515

PubMed: 32061965 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106206

PubMed: 32018066 ( click the link to review the publication )

EBioMedicine, 2019, 47:142-155

PubMed: 31492557 ( click the link to review the publication )

Cancer Lett, 2019, 440-441:116-125

PubMed: 30343113 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):397

PubMed: 31113934 ( click the link to review the publication )
Front Pharmacol, 2019, 10:836

PubMed: 31440159 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(6):1495-1507

PubMed: 31028540 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 116:105610

PubMed: 31518663 ( click the link to review the publication )

Front Pediatr, 2019, 7:228

PubMed: 31231624 ( click the link to review the publication )

Endocr J, 2019, 10.1507/endocrj.EJ19-0015

PubMed: 31105125 ( click the link to review the publication )

Viruses, 2019, 11(12)

PubMed: 31842327 ( click the link to review the publication )

Chin J Dent Res, 2019, 22(4):221-227

PubMed: 31859282 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Theranostics, 2018,

PubMed: 30083255 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(2):127-136

PubMed: 29156121 ( click the link to review the publication )

Oncol Lett, 2018, 16(4):4526-4536

PubMed: 30214587 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):317-325

PubMed: 29928417 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9425-9441

PubMed: 29507700 ( click the link to review the publication )

Mucosal Immunol, 2018, 11(6):1663-1673

PubMed: 30082707 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1274-1285

PubMed: 28892080 ( click the link to review the publication )

Cancer Res, 2017, 77(3):790-801

PubMed: 27940576 ( click the link to review the publication )

Theranostics, 2017, 7(5):1389-1406

PubMed: 28435473 ( click the link to review the publication )

J Transl Med, 2017, 15(1):46

PubMed: 28231855 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:1235-1241

PubMed: 28320090 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2657-2666

PubMed: 29048666 ( click the link to review the publication )

J Pharm Biomed Anal, 2017, 145:586-592

PubMed: 28783595 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 490(2):567-573

PubMed: 28624453 ( click the link to review the publication )

Oncol Lett, 2017, 14(5):5959-5965

PubMed: 29113232 ( click the link to review the publication )
Biochim Biophys Acta Gen Subj, 2017, 1861(2):264-275

PubMed: 27894925 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29245915 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28978083 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51748-51757

PubMed: 28881683 ( click the link to review the publication )

Oncotarget, 2017, 8(46):80651-80665

PubMed: 29113333 ( click the link to review the publication )

J Pharm Sci, 2016, 105(3):1113-23

PubMed: 26886329 ( click the link to review the publication )

Oncotarget, 2016, 7(19):28435-47

PubMed: 27078846 ( click the link to review the publication )

Oncotarget, 2016, 7(35):57077-57085

PubMed: 27494851 ( click the link to review the publication )

J Biol Chem, 2015, 290(52):30988-1002

PubMed: 26518876 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1115-27

PubMed: ( click the link to review the publication )

Int J Pharm, 2015, 496(2):382-91

PubMed: 26468038 ( click the link to review the publication )

Int J Biochem Cell Biol, 2015, 69:132-41

PubMed: 26510582 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:5851-62

PubMed: 26586936 ( click the link to review the publication )

Biochem Bioph Res Co, 2015, 10.1016/j.bbrc.2015.03.008

PubMed: 25770423 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2699-708

PubMed: 25964548 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(2):498-508

PubMed: 24372551 ( click the link to review the publication )

J Cell Physiol, 2014, 10.1002/jcp.24919

PubMed: 25546329 ( click the link to review the publication )

Blood, 2011, 118(22):5891-900

PubMed: 21865341 ( click the link to review the publication )

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description

Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Targets

COX-2 ^[1]
(Sf9 cells)

40 nM

In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. ^[1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A549	NUDnd\|ZGTnWwY4Tpc44hSXO\|YYm=	NVXRUGFUOC5zLUOwJO69VQ>?	NXKwVYRpPDhiaB?=		NUfhUXN7cW6mdXPld{BKS0GPLUGg[ZhxemW\|c3nvckBwdiCkb4ToJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wx?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjVzM{G3Nkc,OjZ3MUOxO\|I9N2F-
H460	MVzGeY5kfGmxbjDBd5NigQ>?	M3\oTlAvOS1\|MDFOwG0>	MUS0PEBp		MV;pcoR2[2W\|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=>	NF\qfpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWxN\|E4Oid-Mk[1NVMyPzJ:L3G+
HKESC-2	M1\qXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWKyNOKh\|ryP	M2Hsb\|Q5yqCqwrC=		M{n4TJNq\26rZnnjZY51dHliaX7jdoVie2W\|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>?	NVjCZZJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0O\|Q3QTNpPkK2OFc1Pjl\|PD;hQi=>
CaES-17	M{fRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkOyNlDDqM7:TR?=	MYi0POKhcMLi		Mknnd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJGlEPTEEoI\hcJVmeyCxZjDvfIFtcXCuYYTpcuKh	NUPRdpM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0O\|Q3QTNpPkK2OFc1Pjl\|PD;hQi=>
HKESC-2	M3XuSGFxd3C2b4Ppd{BCe3OjeR?=	MknQNlDDqM7:TR?=	NUDYWFJLPDkEoHlCpC=>		NXLTVXZ3emWmdXPld{BwgGGuaYDsZZRqdi2rbnT1Z4VlKGGyb4D0c5Nqew>?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5NE[5N{c,OjZ2N{S2PVM9N2F-
CaES-17	M1;URmFxd3C2b4Ppd{BCe3OjeR?=	NX3DeIlUOjEEoN88US=>	NF7XXHY1QMLiaNMg		MX3y[YR2[2W\|IH;4ZYxqeGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz	Mk[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2N{S2PVMoRjJ4NEe0Olk{RC:jPh?=
A549	MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPjOU0yPjBizszN	M4\rdVQ5yqCqwrC=	NF6yd2FFVVOR	MkC0TWM2OD1zNkOuOEDPxE1?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR4NE[0N{c,OjZ2NkS2OFM9N2F-
HCC827	NEmyWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nwOlUuOTZyIN88US=>	M3TidlQ5yqCqwrC=	NHrBOHZFVVOR	M{DJUmlEPTB;NkmuNkDPxE1?	NF24[GU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS2OFY1Oyd-Mk[0OlQ3PDN:L3G+
A549	M{PzbWFxd3C2b4Ppd{BCe3OjeR?=	MYC4NEDDvU1?	MnrrOFjDqGkEoB?=	Ml34SG1UVw>?	MX7pcoR2[2W\|IHHwc5B1d3Orcx?=	M2nPeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NE[0OlQ{Lz5{NkS2OFY1OzxxYU6=
HCC827	MlzXRZBweHSxc3nzJGF{e2G7	MmSzPFAhyrWP	MWS0POKhcMLi	Mo\GSG1UVw>?	Mo\jbY5lfWOnczDhdI9xfG:\|aYO=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR4NE[0N{c,OjZ2NkS2OFM9N2F-
SGC-7901/DDP	NYPRcVJXTnWwY4Tpc44hSXO\|YYm=	NU\KcohJOTEEoNM1US=>	NWHXUml5OjRiaB?=		Mm\IbY5pcWKrdIOgZ5lkdG:xeInn[Y5ie2VvMjDhcoQhWC2pbInjc5Bzd3SnaX6g[ZhxemW\|c3nvci=>	NXfVUlJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NFc3PTNpPkK2OFA4PjV\|PD;hQi=>
SGC-7901	M2DsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmXjNlTDqGkEoB?=		NFL6bGxKSzVyPUGxOU4xQCEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjRyN{[1N{c,OjZ2MEe2OVM9N2F-
SGC-7901/DDP	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3XrWlI1yqCqwrC=		NYnDRWsyUUN3ME2zOU41PSEQvF2=	M1\zS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEC3OlU{Lz5{NkSwO\|Y2OzxxYU6=
SGC-7901/DDP	MojkRZBweHSxc3nzJGF{e2G7	NHTkcXkyOMLiwsXN	NHXsNnozPCCq		MlyybY5lfWOnczDhdI9xfG:\|aYOgZ49u[mmwZXSge4l1cCC5aYToJINqe3CuYYTpci=>	NFrPdnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSwO\|Y2Oyd-Mk[0NFc3PTN:L3G+
SGC-7901/DDP	MXjGeY5kfGmxbjDBd5NigQ>?	NUHOOpRCOTEEoNM1US=>	M{TsWVI1KGh?		NGHMVGtqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBRNWeueXPvdJJwfGWrbjD0bJJwfWeqIHLsc4NscW6pIFXQNkwh[W6mIHnuZYN1cX[jdHnu[{BRU0FiYX7kJGNTTUMEoB?=	MlXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2MEe2OVMoRjJ4NEC3OlU{RC:jPh?=
SGC-7901/DDP	MXjGeY5kfGmxbjDBd5NigQ>?	MXuxNOKhyrWP	M37qXVI1KGh?		NH;DbXFk[XW\|ZYOgZUBu[XKtZXSg[IVkemWjc3WgbY4hfGinIHzleoVtKG:oIFLjcE0zKHC{b4TlbY4>	MoPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2MEe2OVMoRjJ4NEC3OlU{RC:jPh?=
H357	MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnPUlM4NjVxMUCg{txO	NFL4cHM1QCCq	MXrEUXNQ	NH;iZ4RqdmirYnn0d{Bk\WyuIHfyc5d1cMLiY3;tZolv\WRid3n0bEBU[WK3dH;jcIF5	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByOUi3OEc,OjZyMEm4O\|Q9N2F-
TAF	MXTGeY5kfGmxbjDBd5NigQ>?	NXL1Z5BiOTEEoNM1US=>	MnH0O{Bl		MYPh[oZm[3S\|IGTBSpMh[WSqZYPpeoUheHKxcHXyeIlmew>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl6N{GyO{c,OjV7OEexNlc9N2F-
TAF	NWfO[IFYTnWwY4Tpc44hSXO\|YYm=	MXGxNOKhyrWP	NITnUGo{OC1zMkCgcYlv		MnKxdI9wemy7IHHm[oVkfHNiZFHreEBxcG:\|cHjvdplt[XSrb36gZ49ve2WzdXXueEB1dyCHR1[gd4lodmGuaX7n	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl6N{GyO{c,OjV7OEexNlc9N2F-
TAF	NWG5RWszTnWwY4Tpc44hSXO\|YYm=	M{nIV\|ExyqEEtV2=	NXX4bol7PDhiaB?=		M3jyVYlv[3KnYYPld{BGT0[UIH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?=	MlTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7OEexNlcoRjJ3OUi3NVI4RC:jPh?=
PANC-1	M{[2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn:wNlAwPjBxMUCwJO69VQ>?	NXriRmR[OjRxNEivO\|IhcA>?		MoK5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NU\2[HNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5O\|MxPjJpPkK1PVc{ODZ{PD;hQi=>
PANC-1	MYDGeY5kfGmxbjDBd5NigQ>?	M17WeFIxNzZyL{GwNEDPxE1?	NUTFSWV3OjRiaB?=		MkLwZZR1\W63YYTzJINmdGxiaX72ZZNqd25iYX7kJI1q\3KjdHnvckBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh	NHyxS3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm3N\|A3Oid-MkW5O\|MxPjJ:L3G+
HeLa	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\aW41yOjEEoN88UeKh	MWqyOOKhcA>?		M2\UNIVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w	MlX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{C0NlMoRjJ3N{ewOFI{RC:jPh?=
SACC-83	MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPnTVkzOMLizszNxsA>	NHjpZZIzPMLiaB?=		M{\BR4VvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w	MonQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{C0NlMoRjJ3N{ewOFI{RC:jPh?=
HeLa	MUHBdI9xfG:\|aYOgRZN{[Xl?	NYHoU\|lUOjEEoN88UeKh	Mo\ONlTDqGh?		NX3QdnJR\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>?	NHrTTVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3NFQzOyd-MkW3O\|A1OjN:L3G+
SACC-83	NWDacVB3SXCxcITvd4l{KEG\|c3H5	NWP1eXg5OjEEoN88UeKh	Mmr5NlTDqGh?		M4TZRoVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5MESyN{c,OjV5N{C0NlM9N2F-
HeLa	NEnHd2hHfW6ldHnvckBCe3OjeR?=	NWfCT3BtOjBxNECvPFAh\|ryP	MW[yOOKhcA>?		M1zjU5VxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV	MofTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{C0NlMoRjJ3N{ewOFI{RC:jPh?=
SACC-83	M1XqZWZ2dmO2aX;uJGF{e2G7	M1LYfVIxNzRyL{iwJO69VQ>?	M4XGeFI1yqCq		MoTSeZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q>	NGPhcWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3NFQzOyd-MkW3O\|A1OjN:L3G+
HLCZ01	NYrTUoRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTN[G4x6oDVNkFCpOK2VQ>?	MlGwOFghcA>?	M4PtWWROW09?	MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MmrKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MkS4PVkoRjJ3N{K0PFk6RC:jPh?=
HLCZ01	NWjje2k5TnWwY4Tpc44hSXO\|YYm=	NVO4OmhEPDEEoN88US=>	NFW2WVUzPCCq	NUTEdW42TE2VTx?=	MWfpcoNz\WG\|ZYOgZYNkfW23bHH0bY9vKG:oIFewM2cyNXCqYYPlJINmdGy\|IHPvcYJqdmWmIIfpeIghUU[QLd8x	NHjIbFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyOFg6QSd-MkW3NlQ5QTl:L3G+
HLCZ01	MoTYRZBweHSxc3nzJGF{e2G7	MlPOOFDDqM7:TR?=	NUT2do15OjRiaB?=	MmnoSG1UVw>?	NXS3eJhS\W6qYX7j[ZMh[XCxcITvd4l{KGOxbXLpcoVlKHerdHigTWZPNc7z	NX;NfYc{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlQ5QTlpPkK1O\|I1QDl7PD;hQi=>
HLCZ01	NVfMb3prTnWwY4Tpc44hSXO\|YYm=	MXO0NOKh\|ryP	NYnE[3BpOjRiaB?=	Ml3hSG1UVw>?	Mo\obY5kemWjc3XzJHRTSUmOIHX4dJJme3Orb36gZ49u[mmwZXSge4l1cCCLboTldoZmem:wLd8x	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{NEi5PUc,OjV5MkS4PVk9N2F-
MGC803	M4DMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLyNE03OCEQvF2=	NYPPSHRPPzJiaB?=		MXvJR\|UxRTR5LkK15qCKyrIkgJm2MlQ{KM7:TR?=	NXfwfmlsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFE{PzhpPkK1O\|AyOzd6PD;hQi=>
SGC7901	NHyyZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTYZYsxNTZyIN88US=>	NXvwcHMxPzJiaB?=		M3q3bGlEPTB;NEOuOVPjiIoEsfMAjVUvOTJizszN	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdyMUO3PEc,OjV5MEGzO\|g9N2F-
MGC803	MYHGeY5kfGmxbjDBd5NigQ>?	M{DWS\|QxyqEQvF2=	NVf0WFI3QC9zNj:yOEBp		MVv1dJJm\3WuYYTzJGNjdC2kIHX4dJJme3Orb36=	M3XtRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CxN\|c5Lz5{NUewNVM4QDxxYU6=
SGC7901	MknZSpVv[3Srb36gRZN{[Xl?	NGC5W4Y1OMLizszN	MnOwPE8yPi9{NDDo		NF7yW5R2eHKnZ4XsZZR{KEOkbD3iJIV5eHKnc4Ppc44>	NX;qVlFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFE{PzhpPkK1O\|AyOzd6PD;hQi=>
MCF-7	NWnQV29vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnX2NU8yOCEQvF2=	MUm3NkBp	M4rwU2ROW09?	MV\lcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>?	NWPOd203RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2Olc2OTBpPkK1OlY4PTFyPD;hQi=>
MDA-MB-231	NX\Fc2gzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHruNYoyNzFyIN88US=>	NYqzbVMzPzJiaB?=	NHvkPZdFVVOR	MYTlcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>?	M1ToblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[3OVExLz5{NU[2O\|UyODxxYU6=
MDA-MB-231	NXSyOVJ1TnWwY4Tpc44hSXO\|YYm=	NHPXd5UxNTRyINM1US=>	M1TQ[VQuOjRiaB?=		NX7kT\|hvcW6lcnXhd4V{KEORWD2yJJBzd3SnaX6g[ZhxemW\|c3nvckBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NF7iPFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW4O\|MzQSd-MkW1PFc{Ojl:L3G+
MCF-7	M{DjVmZ2dmO2aX;uJGF{e2G7	M1S2WVAuPDBiwsXN	M4fBPVQuOjRiaB?=		MV;lcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW\|c3nvcuKh	NELLUYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW4O\|MzQSd-MkW1PFc{Ojl:L3G+
MCF7-MX	MoDPSpVv[3Srb36gRZN{[Xl?	NETjeIQxNTRyINM1US=>	M4nGW\|QuOjRiaB?=		NYLpW\|JH\W6qYX7j[ZMhfGinIHXm[oVkfHNib3[gWHBCKG:wIFHCR2czKGW6cILld5Nqd28EoB?=	Ml3iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OEezNlkoRjJ3NUi3N\|I6RC:jPh?=
MDA-MB-231	MWTGeY5kfGmxbjDBd5NigQ>?	M2T6OlAuPDBiwsXN	M{\GV\|QuOjRiaB?=		MonFd5RqdXWuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBCSkOJMjD1dEB1dyB2LkK3JJRqdWW\|IITvJINwdnS{b3ygcIV3\WxiYomgNVIhcMLi	Mnm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OEezNlkoRjJ3NUi3N\|I6RC:jPh?=
A2780	M3n2UmZ2dmO2aX;uJGF{e2G7	M1Txc\|UwOTBxMUWg{txO	MVq0PEBp		NUG5V3I5\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M1P4bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEK0PFk5Lz5{NUSyOFg6QDxxYU6=
SKOV3	NG\GT4xHfW6ldHnvckBCe3OjeR?=	NE\UU242NzFyL{G1JO69VQ>?	NXn0UYxlPDhiaB?=		NXLRVVNw\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M3n2[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEK0PFk5Lz5{NUSyOFg6QDxxYU6=
A2780	NFPRPZRHfW6ldHnvckBCe3OjeR?=	NWDCOJhsPS9zMD:xOUDPxE1?	NG\lNVI1QCCq		MX;lcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv	MkfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MkS4PVgoRjJ3NEK0PFk5RC:jPh?=
SKOV3	Mn6xSpVv[3Srb36gRZN{[Xl?	M4fSTVUwOTBxMUWg{txO	MnTZOFghcA>?		MYHlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv	NV3aOpJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NlQ5QThpPkK1OFI1QDl6PD;hQi=>
A2780	NGfxOnpHfW6ldHnvckBCe3OjeR?=	MoDnOU8yOC9zNTFOwG0>	M4K2ZVQ5KGh?		MXfk[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5?	M1e0clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEK0PFk5Lz5{NUSyOFg6QDxxYU6=
SKOV3	NVLWUmZNTnWwY4Tpc44hSXO\|YYm=	NEW2XnY2NzFyL{G1JO69VQ>?	NHLqNpE1QCCq		NFfJWWZl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6=	Ml72QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MkS4PVgoRjJ3NEK0PFk5RC:jPh?=
A2780	MUTGeY5kfGmxbjDBd5NigQ>?	NVzLd4t[PS9zMD:xOUDPxE1?	M3\3PFEhcA>?		NHfqSpdqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NFLFSlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSyOFg6QCd-MkW0NlQ5QTh:L3G+
SKOV3	NEHm[mpHfW6ldHnvckBCe3OjeR?=	M{fFeVUwOTBxMUWg{txO	M{C4O\|EhcA>?		MYXpcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M2T0[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEK0PFk5Lz5{NUSyOFg6QDxxYU6=
HCT-15	MUHGeY5kfGmxbjDBd5NigQ>?	MmnJNVAuPTBizszN	NV;jR4dkPi1\|NjDo		NV72[3hqcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	M136[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkG4NFI5Lz5{NUKxPFAzQDxxYU6=
HT-29	NFjYVGlHfW6ldHnvckBCe3OjeR?=	NXL0dm5OOTBvNUCg{txO	M4C1VFYuOzZiaB?=		NYDtNphKcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	NFfnWlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKxPFAzQCd-MkWyNVgxOjh:L3G+
HSC3	NUXJO3BwS2WubDDWbYFjcWyrdImgRZN{[Xl?	MkXVNQKBmzRyIN88US=>	NIWyd4M1QCCq		M4LyfGlEPTB;MkWuOeKyOS55OECg{txO	Mn7pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzOUi3PFkoRjJ3MUm4O\|g6RC:jPh?=
HSC3	NX7DVmxoSXCxcITvd4l{KEG\|c3H5	NHOzb4kzPSEQvF2=	MknjOFghcA>?		MmfKbY5lfWOnczDhdI9xfG:\|aYO=	M3zHXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUm4O\|g6Lz5{NUG5PFc5QTxxYU6=
HSC3	MmHLSpVv[3Srb36gRZN{[Xl?	Mne3NlUh\|ryP	NYfXeJMzPDhiaB?=		MmLt[ZhpcWKrdIOgd4lodmmoaXPhcpRtgSC{ZXT1Z4VlKG2rZ4LheIlwdiClb33ibY5m\CC5aYToJGNGXA>?	NX7wW5p4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxPVg4QDlpPkK1NVk5Pzh7PD;hQi=>
HSC3	M3n6VWZ2dmO2aX;uJGF{e2G7	NFflfIEzPSEQvF2=	M{LaSlQ5KGh?		NGXhNXZqdmirYnn0d{BJW0N\|IHPlcIwhcW64YYPpc44h[2:vYnnu[YQhf2m2aDDDSXQ>	M3;rcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUm4O\|g6Lz5{NUG5PFc5QTxxYU6=
HSC3	MU\GeY5kfGmxbjDBd5NigQ>?	NXPSTlFMOjVizszN	NUXPOWJTPzJiaB?=		MWLk[YNz\WG\|ZYOgUW1RNTJiYX7kJG1OWC17IIDyc5RmcW6\|wrC=	Ml3EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzOUi3PFkoRjJ3MUm4O\|g6RC:jPh?=
201T	NUG0PVZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWHXdmRHPzJiaB?=	NGrw[XBFVVOR	M1zqUWlEPTB;NEiuOkDDvU1?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB3N{m0NUc,OjVyNUe5OFE9N2F-
273T	NX\qW4J1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1\3WlczKGh?	MX7EUXNQ	NWjhWpNZUUN3ME24NE42KML3TR?=	MkTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUe5OFEoRjJ3MEW3PVQyRC:jPh?=
Hep-2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjtclM{OC93MD:xNFAh\|ryP	NEnlSGYyOi9{ND:zOk81QCCq	MYXEUXNQ	NWLrZYg6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NHWzeXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5PFU3PCd-MkS5PVg2PjR:L3G+
Hep-2	NYPndpl3SXCxcITvd4l{KEG\|c3H5	NEC2OHM2OCEQvF2=	NWLweZliOC12ODDo	NGf2OFJFVVOR	MX3pcoR2[2W\|IHHwc5B1d3OrczDpckBiKHSrbXWg[IVx\W6mZX70JI1idm6nch?=	NYjpclFpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVg2PjRpPkK0PVk5PTZ2PD;hQi=>
Hep-2	MYDGeY5kfGmxbjDBd5NigQ>?	NFKwO3c2OCEQvF2=	NVLkWnU{OC12ODDo	MnPCSG1UVw>?	NVK0ZVRUemWmdXPld{B1cGVidHXsc41memG\|ZTDhZ5Rqfmm2eTDndoFlfWGubIm=	NGjPfFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5PFU3PCd-MkS5PVg2PjR:L3G+
Hep-2	NXTZ[VFwTnWwY4Tpc44hSXO\|YYm=	Mnj6OVAh\|ryP	NX;hc4RbOC12ODDo	NYHvWVAxTE2VTx?=	M12zToRm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIHjUSXJV	NXLzZ49SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVg2PjRpPkK0PVk5PTZ2PD;hQi=>
SGC-7901	M2G3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33kfFExNzVyL{GwNEDPxE1?	MYmyOE81QC95MjDo	MVzEUXNQ	NXrsRpNxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MnuxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUK5OVgoRjJ2OUmyPVU5RC:jPh?=
MKN-45	MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4Xl[\|ExNzVyL{GwNEDPxE1?	M1fE[lI1NzR6L{eyJIg>	NFnISllFVVOR	M3vON4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NGntWpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5Nlk2QCd-MkS5PVI6PTh:L3G+
SGC-7901	MX\GeY5kfGmxbjDBd5NigQ>?	MYexNE82OC9zMECg{txO	MWG0PEBp	NHT6dnBFVVOR	M2rq[IRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NFrsTlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5Nlk2QCd-MkS5PVI6PTh:L3G+
MKN-45	NGOyVWdHfW6ldHnvckBCe3OjeR?=	M17XfVExNzVyL{GwNEDPxE1?	NWHkTJpUPDhiaB?=	MkPNSG1UVw>?	M3qxPIRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NIHsWZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5Nlk2QCd-MkS5PVI6PTh:L3G+
C666-1	MVjDfZRwfG:6aXPpeJkhSXO\|YYm=	M3\NSlIxNThyIN88US=>	M{[4[\|I1KGh?		Ml74[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=>	NE\COHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi1OFg{QCd-MkS4OVQ5Ozh:L3G+
CNE-1	MV7DfZRwfG:6aXPpeJkhSXO\|YYm=	MVeyNE05OCEQvF2=	NEO5TmkzPCCq		NFfiT3Bl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh	M2T2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEW0PFM5Lz5{NEi1OFg{QDxxYU6=
CNE-2	NYfvem44S3m2b4TvfIlkcXS7IFHzd4F6	Mk\ZNlAuQDBizszN	MU[yOEBp		M3jWXYRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh3NEizPEc,OjR6NUS4N\|g9N2F-
C666-1	MY\DfZRwfG:6aXPpeJkhSXO\|YYm=	M2i0UlYxKM7:TR?=	NX7nW\|hTPyCm		NUj0bZJ7\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI>	MlroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUS4N\|goRjJ2OEW0PFM5RC:jPh?=
CNE-1	NYrwNGlmS3m2b4TvfIlkcXS7IFHzd4F6	NYfq[4FWPjBizszN	Mn3DO{Bl		Mnni[Y5p[W6lZYOgdoFlcWG2aX;uJIN6fG:2b4jpZ4l1gSC2aILveYdpKEORWD2yMYRmeGWwZHXueEBu[W6wZYK=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh3NEizPEc,OjR6NUS4N\|g9N2F-
SNU-1041	NX;BVYIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HjblAuPDBizszN	NHHzfVM1QCCq		NFK3cnpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NWjrZmNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PVI4ODNpPkK0OlkzPzB\|PD;hQi=>
SNU-1041	MVPGeY5kfGmxbjDBd5NigQ>?	MUCyNE8{OCEQvF2=	NUG3XHltPCCq		NHnq[pBqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>?	NYH2ZohsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PVI4ODNpPkK0OlkzPzB\|PD;hQi=>
SNU-1041	NH;vNFhHfW6ldHnvckBCe3OjeR?=	MWWwMVQxKM7:TR?=	Ml7sOEBp		M2Hn[ZVxNXKnZ4XsZZRmeyCFSF;QxsBi\nSncjD0doVifG2nboSge4l1cCCqaXfoJINwdmOnboTyZZRqd26\|	M3jPdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkmyO\|A{Lz5{NE[5NlcxOzxxYU6=
SGC-7901	NUn1e2pCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPMc3E2OC1zMkWg{txO	M1LkflI1NzR6L{eyJIg>		MoDFbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M4LQRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nke2N\|k1Lz5{NE[3OlM6PDxxYU6=
SGC-7901	NGDvRZhCeG:ydH;zbZMhSXO\|YYm=	NEf6eVEyODBizszN	MoDFO\|IhcA>?		MoTHbY5lfWOnczDhdI9xfG:\|aYO=	MmfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{[zPVQoRjJ2Nke2N\|k1RC:jPh?=
SGC-7901	NInD[oxHfW6ldHnvckBCe3OjeR?=	NUfN[YV7PzVxMUCwM\|EzPSEQvF2=	MmPGNlQwPDhxN{KgbC=>		NEnsdWJqdmO{ZXHz[ZMh[2G\|cHHz[U05KGGwZDCtPUBuWk6DIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKG2jbn7ldi=>	NYCwXYZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|Y{QTRpPkK0Olc3Ozl2PD;hQi=>
LMeC	NGnsR\|hHfW6ldHnvckBCe3OjeR?=	NYC1R4tsOjBxNUCg{txO	NWDBT4tpPDhiaB?=		NH32RWxl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhS0:[LUKgdJJwfGWrbh?=	NYjUVZM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OVY4PDZpPkK0OlU3PzR4PD;hQi=>
CMeC-1	MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mk\GNlAwPTBizszN	M{jCW\|Q5KGh?		MoSwbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MmfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NU[3OFYoRjJ2NkW2O\|Q3RC:jPh?=
LMeC	M2XBPGNmdGxiVnnhZoltcXS7IFHzd4F6	M1TvPVIxNzVyIN88US=>	MWe0PEBp		MVvpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ3Nke0Okc,OjR4NU[3OFY9N2F-
CMeC-1	Ml\RSpVv[3Srb36gRZN{[Xl?	NG\aVY0zOC93MDFOwG0>	MlTLOFghcA>?		MUfpcoR2[2W\|IFexMXMh[XK{ZYP0	Mo\JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NU[3OFYoRjJ2NkW2O\|Q3RC:jPh?=
LMeC	NF7Ycm9HfW6ldHnvckBCe3OjeR?=	M{DPVVIxNzVyIN88US=>	MX:0PEBp		MoTHbY5lfWOnczDHNU1UKGG{cnXzeC=>	Mmr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NU[3OFYoRjJ2NkW2O\|Q3RC:jPh?=
CMeC-1	NH3rN2dHfW6ldHnvckBCe3OjeR?=	MmfuNlAwPTBizszN	Mke4OFghcA>?		NFXRNY5l\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NIj5PIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[1Olc1Pid-MkS2OVY4PDZ:L3G+
LMeC	M1f0UmZ2dmO2aX;uJGF{e2G7	NH7DdIUzOC93MDFOwG0>	MnHxOFghcA>?		M1zufYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M1L1OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkW2O\|Q3Lz5{NE[1Olc1PjxxYU6=
CMeC-1	MXfGeY5kfGmxbjDBd5NigQ>?	M2D3TVIxNzVyIN88US=>	NHT2PXc1QCCq		MWPpcoR2[2W\|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u	M2\nblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkW2O\|Q3Lz5{NE[1Olc1PjxxYU6=
LMeC	NYn4UVZkTnWwY4Tpc44hSXO\|YYm=	MlTVNlAwPTBizszN	M3v4OFQ5KGh?		MV3pcoR2[2W\|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u	NY\vU3RxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OVY4PDZpPkK0OlU3PzR4PD;hQi=>
OVCAR-3	MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M1PKSFExKML3TR?=	M2L4PFEhcA>?		M3;6VIVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA>	NWCyd5FoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NlAzOjdpPkK0OVIxOjJ5PD;hQi=>
OVCAR-3	MkXLRZBweHSxc3nzJGF{e2G7	M1fGVlExKML3TR?=	M4PWSVEhcA>?		MULwdo9ud3SnczDwZYNtcXSjeHXsMYlv\HWlZXSgZZBweHSxc3nzxsA>	M{f1VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUKwNlI4Lz5{NEWyNFIzPzxxYU6=
OVCAR-3	M3Ppc2Z2dmO2aX;uJGF{e2G7	NGDEWFgyOCEEtV2=	MWexJIg>		MVHlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmNToEoB?=	NX3O[Gh[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NlAzOjdpPkK0OVIxOjJ5PD;hQi=>
OVCAR-3	NX7oXItwTnWwY4Tpc44hSXO\|YYm=	MYKxNEDDvU1?	MYKxJIg>		M4XycIRwf25vcnXneYxifGW\|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV{MEKyO{c,OjR3MkCyNlc9N2F-
OVCAR-3	NXXlXYwyTnWwY4Tpc44hSXO\|YYm=	NYDDbpNVOTBiwsXN	NYnafmdbOSCq		NYfRdGN7cW6qaXLpeJMheGGlbHn0ZZhmdC2rbnT1Z4VlKEGtdDDwbI9{eGixconsZZRqd25?	NFjqVVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyNFIzPyd-MkS1NlAzOjd:L3G+
CF33	NEHQSYdHfW6ldHnvckBCe3OjeR?=	MmHNNVAxKM7:TR?=	MlPsNlQhcA>?		NX;UW4xwcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBEV1hvMjDwdo91\WmwIHX4dJJme3Orb36=	NHX2O\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWwN\|c5Oid-MkS1NFM4QDJ:L3G+
CF33	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHv5bGgyOC1zMECg{txO	NFXmPFExNTRiZB?=		MUDpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NFu4cm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWwN\|c5Oid-MkS1NFM4QDJ:L3G+
CF33	NGDlfoNHfW6ldHnvckBCe3OjeR?=	MkPxNVAuOTByIN88US=>	NGrGbnk1NTJ2IHi=		MljU[IVkemWjc3XzJINmdGy\|IHnuJJRp\SCVIIDoZZNmKGGwZDDpcoNz\WG\|ZYOgZ4VtdHNiaX6gS\|AwTzFiYYLy[ZN1	MljpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MEO3PFIoRjJ2NUCzO\|gzRC:jPh?=
LNCaP	NYnVSVh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG[4b2UzNzVxMUCg{txO	NELwT2I6PiCq		NV\wN\|VRcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7Nkm3PEc,OjR{OU[5O\|g9N2F-
LNCaP	NWH0OosySXCxcITvd4l{KEG\|c3H5	MlfaNk82NzFyIN88US=>	MonQPVYhcA>?		NIDXe\|BqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=>	NGHvfpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5Olk4QCd-MkSyPVY6Pzh:L3G+
PC-3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17iTVAuPTBizszN	MnrIOFjjiImq		NUHNeWF6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MnHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMke4PFIoRjJ2MUK3PFgzRC:jPh?=
PC-3	NWrDUGg{S2WubDDWbYFjcWyrdImgRZN{[Xl?	MoKwNE0yODBizszN	MkX6O\|IhcA>?		M3rrSoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NECxOYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyO\|g5Oid-MkSxNlc5QDJ:L3G+
HCA-7	MYDGeY5kfGmxbjDhd5NigQ>?		MnrnO\|IhcHK\|		NXvMU5dQUW6qaXLpeIlwdiCxZjDJUE0y[mW2YT3pcoR2[2WmIGDHSVIheHKxZIXjeIlwdiCrbjDoeY1idiCKQ1GtO{Bk\WyuczDh[pRmeiB5MjDodpMh[nliRVnBMEBGSzVyIE2gNE4xODFzNTFOwG0v	NEDoe3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWxOlI5Oid-MkK1NVYzQDJ:L3G+
CHO	MVLGeY5kfGmxbjDhd5NigQ>?				NX34OJV{UW5idnn0do8hcW6qaXLpeI9zgSCyb4TlcoN6KGGpYXnud5QhcHWvYX6gR29ZNTJiaX6gd5Ri[my7IITyZY5{\mWldHXkJINpcW6nc3WgbIFue3SncjDveoFzgSBqQ1jPLUBk\WyuczygTWM2OCB;IECuNFAzKM7:TT6=	NETpcW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEW3OlY5PCd-MUC1O\|Y3QDR:L3G+
CHO	MUnGeY5kfGmxbjDhd5NigQ>?				MmjETY5pcWKrdHnvckBw\iCSR1WtNkBxem:mdXP0bY9vKGmwIFPIU{Bk\WyuczDlfJBz\XO\|aX7nJIh2dWGwIFPPXE0zNCCLQ{WwJF0hOC5yMEKg{txONg>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODV5Nk[4OUc,OTB3N{[2PFU9N2F-
CHO	NFnaO5VHfW6ldHnvckBie3OjeR?=				NVXUXHh1UW5idnn0do8heG:2ZX7jfUBi\2GrboP0JIh2dWGwIGDyc5N1[WeuYX7kbY4hTy:KIIP5cpRp[XOnIEKgbY4hfHKjboPm[YN1\WRiQ1jPJINmdGy\|LDDJR\|UxKD1iMD6wNFIh\|ryPLh?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODF7N{m3NEc,OTBzOUe5O\|A9N2F-
CHO	NFT5OXBHfW6ldHnvckBie3OjeR?=				MU\Jcohq[mm2b4L5JI9nKGi3bXHuJHBzd3O2YXfsZY5lcW5iRz;IJJN6dnSqYYPlJFIh\XiycnXzd4VlKGmwIFPIU{Bk\WyuczygTWM2OCB;IECuNFAzKM7:TT6=	M1fETlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NkSzPVQzLz5zMk[0N\|k1OjxxYU6=
synovial cells	M4fxTWZ2dmO2aX;uJIF{e2G7				NGT3O3dKdmirYnn0c5J6KGWoZnXjeEBwdiCycn;keYN1cW:wIH;mJIN6[2yxb4j5[4Vv[XOnLUKgLGNQYC1{KTDwdo9{fGGpbHHu[IlvKEV{IDjQS2UzMSCrbjDoeY1idiCLTEGtZoV1[SC\|dHnteYxifGWmIIP5co93cWGuIHPlcIx{NCCLQ{WwJF0hOC5yMEe5JO69VS5?	NVn4bpI1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC4NlE4OTZpPkGwPFIyPzF4PD;hQi=>
RAW264.7	M4PGT2Z2dmO2aX;uJIF{e2G7				NGSyR5lKdmirYnn0bY9vKG:oIFPPXE0zKGmwIH3veZNmKFKDV{K2OE44KGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIFzQV{1qdmS3Y3XkJHBITTJicILv[JVkfGmxbjD0doVifGWmIIDybY9zKHSxIFzQV{BkcGGubHXu[4Uh[nliZX76fY1mKGmvbYXuc4F{e2G7LDDJR\|UxKD1iMD6wNFg4KM7:TT6=	M1j2[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkW2OlYzLz5{NE[1OlY3OjxxYU6=
HEK293	M2LVWWZ2dmO2aX;uJIF{e2G7				MXPJcohq[mm2aX;uJI9nKGOub37l[EBUfHmub4Doc5JiKHCrc4TpcIxifGFiYXzwbIEuS0FiZYjwdoV{e2WmIHnuJIh2dWGwIFjFT\|I6OyClZXzsd{BjgSC\|dH;wdIVlNW[ub4egR28zKGG\|c3H5MEBMcSB;IECuNFM1OiEQvF2u	MlHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3MkC1O\|coRjF7NUKwOVc4RC:jPh?=
SF9	NX\kbYxHTnWwY4Tpc44h[XO\|YYm=				M{jvS2lvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQdo9{fGGpbHHu[IlvKEdxSDDzfY51cGG\|ZTCyJIV5eHKnc4Pl[EBqdiC\|Zj25JINmdGy\|IHnu[oVkfGWmIIfpeIgh[mGldXzveolzfXNuIFnDOVAhRSByLkCzOkDPxE1w	NFHXNWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNE[5PFE6OCd-MUS2PVgyQTB:L3G+
SF9	MmHwSpVv[3Srb36gZZN{[Xl?				MUPJckB3cXS{bzDpcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5icnXjc41jcW6jboSgdJJwe3SjZ3zhcoRqdiCJL1igd5lvfGijc3WgNkBmgHC{ZYPz[YQhcW5ic3[tPUBk\WyuczDpcoZm[3SnZDD3bZRpKGKjY4Xsc5ZqenW\|LDDJR\|UxKD1iMD6wN\|Yh\|ryPLh?=	NYrYO\|h{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWwNlYxPTBpPkG1NFI3ODVyPD;hQi=>
CHO	NEHXdpVHfW6ldHnvckBie3OjeR?=				NUG5SplIUW6qaXLpeIlwdiCxZjDDU3gzKGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhdoFkcGmmb37pZ{Bi[2mmLYP0bY12dGG2ZXSgVGdGOiCycn;keYN1cW:wIHL5JIVvgnmvZTDpcY12dm:jc4PhfUwhUUN3MDC9JFAvODN4IN88UU4>	NX3UcIs{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW1OlYzQTBpPkG1OVY3OjlyPD;hQi=>
insect cells	M4rR[mZ2dmO2aX;uJIF{e2G7		M2rJb\|EhdWmw		MXvJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEORWEKg[ZhxemW\|c3XkJIlvKGmwc3XjeEBk\WyuczD1d4lv\yCjcnHjbIlld26rYzDhZ4llKGG\|IIP1ZpN1emG2ZTDpcoN2[mG2ZXSg[o9zKDFibXnuJJBzcW:{IITvJJN2[nO2cnH0[UBi\GSrdHnvckBu\WG\|dYLl[EBnd3JiMkWgd4VkeyCkeTDUUXBFNWKjc3XkJINpem:vb3flcolkKGG\|c3H5MEBKSzVyIE2gNE4xPDJizszNMi=>	M3;NbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGwNlcxLz5{M{CxNFI4ODxxYU6=
HNSCC 1483	MXHGeY5kfGmxbjDhd5NigQ>?		NXLPNnNWOzBibXnudy=>		NF;TSYFKdmirYnn0bY9vKG:oIFPPXE0zKGmwIHj1cYFvKEiQU1PDJFE1QDNiY3XscJMhfXOrbnegX\|E1S11iYYLhZ4hq\G:waXOgZYNq\CCjczDzeYJ{fHKjdHWgdJJmcW6ldXLheIVlKG[xcjCzNEBucW6\|IHLl[o9z\SC\|dXLzeJJifGViYXTkbZRqd25ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{whUUN3MDC9JFAvODV2IN88UU4>	NXLOZllURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOlM5QTRpPkKyNlY{QDl2PD;hQi=>
J774	NYW1Z5VLTnWwY4Tpc44h[XO\|YYm=				NVLxW\|ZrUW6qaXLpeIlwdiCxZjDDU3gzKGmwIFzQV{1{fGmvdXzheIVlKEp5N{SgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCSR1WyJIxmfmWuczDifUBz[WSrb3ntcZVvd2G\|c3H5MEBKSzVyIE2gNE4xPiEQvF2u	Mn60QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd7MUW4OVQoRjF5OUG1PFU1RC:jPh?=
J774	M1X4PWZ2dmO2aX;uJIF{e2G7		MV2xOUBucW6\|		MorrTY5pcWKrdHnvckBw\iCFT2iyJIlvKEySUz3zeIlufWyjdHXkJI1wfXOnIFq3O\|Qh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDQS2UzKHC{b3T1Z5Rqd25iYX\0[ZIhOTVibXnud{BjgSC{YXTpc4ludXWwb3Hzd4F6NCCLQ{WwJF0hOC5yNjFOwG0v	M2fLelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{WyPVU4Lz5zOEe1Nlk2PzxxYU6=
J774	NVO5W\|VKTnWwY4Tpc44h[XO\|YYm=		NE[yTIczPCCqcoO=		NEXNN\|lKdmirYnn0bY9vKG:oIFPPXE0zNW2nZHnheIVlKFCJRUKgdJJw\HWldHnvckBqdiCOUGOtd5RqdXWuYYTl[EBud3W\|ZTDKO\|c1KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDyZYRqd2mvbYXuc4F{e2G7LDDJR\|UxKD1iMD6wOlEh\|ryPLh?=	M4nFU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUmyNVc3Lz5{MUm5NlE4PjxxYU6=
J774	Ml\zSpVv[3Srb36gZZN{[Xl?				MYjJcohq[mm2aX;uJI9nKEORWEKgbY4hdW:3c3WgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKFCJRUKgdJJw\HWldHnvckBjgSC{YXTpc4ludXWwb3Hzd4F6NCCLQ{WwJF0hOC5yNkGg{txONg>?	NUTzZohFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PFA1PDRpPkKzOlgxPDR2PD;hQi=>
SF9	M1vZZ2Z2dmO2aX;uJIF{e2G7				NVfyO3hLUW6qaXLpeIlwdiCxZjDoeY1idiCFT2iyJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz3pcoZm[3SnZDDTSlkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhdoFkcGmmb37pZ{Bi[2mmLYP0bY12dGG2ZXSgVGdGOiCycn;keYN1cW:wIITy[YF1\WRiMTDodkBj\W[xcnWgZZJi[2irZH;ubYMh[WOrZDDjbIFtdGWwZ3WgZpkh\W68eX3lJIludXWwb3Hzd4F6NCCLQ{WwJF0hOC5yNkOg{txONg>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV{MEW3N{c,OTl3MkC1O\|M9N2F-
COS	MnfxSpVv[3Srb36gZZN{[Xl?				MX3Jcohq[mm2aX;uJI9nKGi3bXHuJIN6[2yxb4j5[4Vv[XOnLUKg[ZhxemW\|c3XkJIlvKEORUzDj[YxteyxiSVO1NEA:KDBwME[4JO69VS5?	NVjve3J7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW0OVQzPDJpPkG1OFU1OjR{PD;hQi=>
COS	M4jWU2Z2dmO2aX;uJIF{e2G7				M{DCeGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:[MjDlfJBz\XO\|ZXSgbY4h[W[{aXPhckBoemWnbjDtc45s\XliQ1;TJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYYLhZ4hq\G:waXOgZYNq\C2\|dHnteYxifGWmIGDHSVIheHKxZIXjeIlwdiC2cnXheIVlKDFiaIKgZoVnd3KnIHHyZYNpcWSxbnnjJIFkcWRiY3jhcIxmdmenIHL5JIVvgnmvZTDpcY12dm:jc4PhfUwhUUN3MDC9JFAvODZ6IN88UU4>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV{MEW3N{c,OTl3MkC1O\|M9N2F-
143982	NHnafGtHfW6ldHnvckBie3OjeR?=				Mm\QTY4hfmm2cn:gbY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDyc5N1[WeuYX7kbY4hTy:KIIP5cpRp[XOnIEKgLGNQYC1{KTDpckAyPDN7OEKgZ4VtdHNuIFnDOVAhRSByLkC3PUDPxE1w	NG\D[mo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMki3O\|U5PCd-MUK4O\|c2QDR:L3G+
J774	NHfQZo9HfW6ldHnvckBie3OjeR?=				NVfaS4xnUW5idnn0do8hcW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KFC{b4P0ZYdt[W6maX6gS{9JKHO7boToZZNmKDJiaX6gcZVzcW6nIFq3O\|Qh[2WubIOsJGlEPTBiPTCwMlA4QSEQvF2u	M{Lwc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OEW3NVQ6Lz5zNUi1O\|E1QTxxYU6=
J774	MlrTSpVv[3Srb36gZZN{[Xl?				MWDJcohq[mm2aX;uJI9nKEORWEKt[IVx\W6mZX70JHBITTJicILv[JVkfGmxbjDpckBNWFNvc4TpcZVt[XSnZDDtc5V{\SCMN{e0JINmdGy\|IHL5JHJKSSxiSVO1NEA:KDBwMEe5JO69VS5?	Mkm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7NUe5N\|EoRjF7OUW3PVMyRC:jPh?=
osteosarcoma cells	Ml;SSpVv[3Srb36gZZN{[Xl?				MnPpTY5pcWKrdHnvckBw\iCScn;zeIFodGGwZHnuJGcwUCC\|eX70bIF{\SB{IHnuJFE1Oy57OD6yJIZzd21iaIXtZY4hd3O2ZX;zZZJkd22jIHPlcIx{NCCLQ{WwJF0hOC5yODFOwG0v	NXq2SVdNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG0OlI6PzZpPkGxOFYzQTd4PD;hQi=>
SF9	NInYcVdHfW6ldHnvckBie3OjeR?=				MWrJcohq[mm2aX;uJI9nKGi3bXHuJGNQYDJiZYjwdoV{e2WmIHnuJJNnQSClZXzsd{whUUN3MDC9JFAvODhizszNMi=>	NX\Pd4JmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[yOVI6OTdpPkG2NlUzQTF5PD;hQi=>
RAW264.7	MYjBcpRqcW6obHHtcYF1d3K7IHHzd4F6				MljMRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBud3W\|ZTDSRXczPjRwNzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIGDHSVIheHKxZIXjeIlwdixiSVO1NEA:KDBwMTFOwG0v	NYnTWFZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNFA6PDhpPkKyNFAxQTR6PD;hQi=>
RAW264.7	NVXyNZdXTnWwY4Tpc44h[XO\|YYm=				NGKxcYJKdmirYnn0bY9vKG:oIFPPXE0zKGmwIH3veZNmKFKDV{K2OE44KGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIFzQV{1qdmS3Y3XkJHBITTJicILv[JVkfGmxbjygTWM2OCB;IECuNVIh\|ryPLh?=	MlfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|NUO3OFEoRjJ\|M{WzO\|QyRC:jPh?=
Sf21	MofySpVv[3Srb36gZZN{[Xl?				M1rSTWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDIbZMufGGpZ3XkJGNQYDJiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoMkGgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKHC{b4P0ZYdt[W6maX6gdJJw\HWldHnvckBjgSCnbor5cYUhcW2vdX7vZZN{[XluIFnDOVAhRSByLkG1JO69VS5?	NVn4XHYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzO\|MzPzFpPkK5N\|c{OjdzPD;hQi=>
Sf21	NWTFT3dUTnWwY4Tpc44h[XO\|YYm=		MVm1JI1qdnN?		M1HwbGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgUk11\XKvaX7hcEBJcXN4LYTh[4dm\CCqdX3hckBEV1hvMjDlfJBz\XO\|ZXSgbY4hSmGldXzveolzfXNiaX7m[YN1\WRiU3[yNUBk\WyuczD1d4lv\yCjcnHjbIlld26rYzDhZ4llKGG\|IIP1ZpN1emG2ZTDwdoVqdmO3YnH0[YQh\m:{IEWgcYlveyCob3zsc5dm\CCkeTDzeYJ{fHKjdHWgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiMTDodkwhUUN3MDC9JFAvOjZizszNMi=>	NXfJbmJvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyPVM4QTVpPkOwNlk{Pzl3PD;hQi=>
MC9	MnXVSpVv[3Srb36gZZN{[Xl?				M1\RXWlvcGmkaYTpc44hd2ZiUFfGNoFxcGFicILv[JVkfGmxbjDpckBiemGlaHnkc45q[yCjY3nkMZN1cW23bHH0[YQhdW:3c3WgUWM6KGOnbHzzMEBKSzVyIE2gNE4{KM7:TT6=	M4qyO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEm4NVUxLz5zOES5PFE2ODxxYU6=
MC9	MUXGeY5kfGmxbjDhd5NigQ>?				NXLjbZQ6UW6qaXLpeIlwdiCxZjDQS2Yz[WyyaHGgdJJw\HWldHnvckBqdiCvb4Xz[UBOSzliY3XscJMtKEmFNUCgQUAxNjRizszNMi=>	MoLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2OUixOVAoRjF6NEm4NVUxRC:jPh?=
293E	MlTSSpVv[3Srb36gZZN{[Xl?				MWfJcohq[mm2aX;uJI9nKGi3bXHuJI1q[3Kxc3;tZYwhWEeHU{Gg[ZhxemW\|c3XkJIlvKDJ7M1WgZ4VtdHNiYomgUGMwVVNxTWOgZY5idHm\|aYOsJGlEPTBiPTCwMlQzPSEQvF2u	NF7GRYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1N\|E5OCd-Mk[2OVMyQDB:L3G+
SF9	NVm1XGRbTnWwY4Tpc44h[XO\|YYm=		M4XwVFE2KG2rboO=		M1PhR2lvcGmkaYTpc44hd2ZiZoXscEBt\W6pdHigdoVkd22kaX7hcpQhcHWvYX6gUk11\XKvaX7hcEBIW1RvdHHn[4VlKEiGQVO2JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDz[lkh[2WubIOgeZNqdmdiQn;jMWx6ey1qQXOpMWFOSyCjczDzeYJ{fHKjdHWgdJJmcW6ldXLheIVlKG[xcjCxOUBucW6\|IH\vcIxwf2WmIHL5JJN2[nO2cnH0[UBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjC2NEBucW6\|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvPjR\|IN88UU4>	NFvJd3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWwNFE{OCd-Mkm1NFAyOzB:L3G+
HT-29	MkjFR5l1d3SxeHnjbZR6KGG\|c3H5		M4fUdlQ5KGi{cx?=		NYTob5BJS3m2b4TvfIlkcXS7IHHnZYlve3RiQ1;YMVIheG:\|aYTpeoUhcHWvYX6gTHQuOjliY3XscJMhfHKjboPm[YN1\WRid3n0bEBETDR2dk\zbHJPSSCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD63JO69VS5?	NX7mNINKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVU4QDdpPkK0Nlk2Pzh5PD;hQi=>
SF9	NXLvbJlkTnWwY4Tpc44h[XO\|YYm=		MkHONVUhdWmwcx?=		MYHJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFzlbZNpdWGwaXGg[I9vd3[jbnmgZ4hi\2G\|aTDi[ZRiNWOjcnLvcolkKGGwaInkdoF{\SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JHNnQSClZXzsd{BqdmO3YnH0[YQh\m:{IEG1JI1qdnNicILpc5IhfG9idHXzeIlv\yCkeTDzeI9xeGWmIH\sc5chS09{IHj5[JJie2ViYYPzZZktKEurIE2gNE44ODVizszNMi=>	MkC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7N{e5OlAoRjJ\|OUe3PVYxRC:jPh?=
HCA-7	MofBR5l1d3SxeHnjbZR6KGG\|c3H5		NVvpemZ7PDhiaILz		NGPHTo9EgXSxdH;4bYNqfHliYXfhbY5{fCCFT2itNkBxd3OrdHn2[UBpfW2jbjDIR2EuPyClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJGNFPDS4NoPoVm5CKGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLke1JO69VS5?	NXi1[ZpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVU4QDdpPkK0Nlk2Pzh5PD;hQi=>
HepG2	MVnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M{izR\|Q5KGi{cx?=		MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwN{[g{txONg>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN2NkO2O{c,OjZ\|NE[zOlc9N2F-
SF9	M4XnPWZ2dmO2aX;uJIF{e2G7		MYKxOUBucW6\|		NITTW3BKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJJJm[2:vYnnuZY51KGi3bXHuJGMufGW{bXnuZYwhTkyDRz;IbZMufGGpZ3XkJGhFSUNzIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC\|ZkmgZ4VtdHNidYPpcochSm:lLVz5d{0pSWNrLVHNR{BieyC\|dXLzeJJifGVicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB4MDDtbY5{KGK7IH\seY9z\XOlZX7j[UBie3NuIFnDOVAhRSBzLkG4OUDPxE1w	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVyMEGzNEc,Ojl3MECxN\|A9N2F-
RAW264.7	M4fhZmFvfGmrbn\sZY1u[XSxcomgZZN{[Xl?		MnjTNVghcHK\|		NEXkN2pCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJHJCXzJ4ND63JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgWG5HNWGucHjhJJNm[3KndHnvckBi\nSncjCxPEBpenNiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSBzLkK4JO69VS5?	M1nRclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nke5OFQyLz5{NE[3PVQ1OTxxYU6=
APC10.1	MYTDfZRwfG:6aXPpeJkh[XO\|YYm=		M1jtSFQ5KGi{cx?=		M4nTZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEORWD2yJJBwe2m2aY\lJI1wfXOnIFHQR\|ExNjFiY3XscJMhfHKjboPm[YN1\WRid3n0bEBETDR2dk\zbHJPSSCxdnXy[ZhxemW\|c3nu[{BJSVNvMjDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNU4{KM7:TT6=	MoDWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUW3PFcoRjJ2Mkm1O\|g4RC:jPh?=
RAW264.7	NHX3NXFCdnSraX7mcIFudWG2b4L5JIF{e2G7		M4Hp[\|MxKG2rboO=		NWHZS3NsSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIIDy[Ylv[3WkYYTl[EBnd3JiM{CgcYlveyCob3zsc5dm\CCkeTDMVHMhe3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KEe{aXXzd{Bie3OjeTygTWM2OCB;IEGuOkDPxE1w	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR2NEC5PEc,OjZ2NESwPVg9N2F-
COS	NGHnfpNHfW6ldHnvckBie3OjeR?=				NEG3e\|JKdmirYnn0bY9vKG:oIHj1cYFvKGO7Y3zvc5h6\2WwYYPlMVEh\XiycnXzd4VlKGmwIFPPV{Bk\WyuczygTWM2OCB;IEGuOlg6KM7:TT6=	MkTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV2NUSyOFIoRjF3NEW0NlQzRC:jPh?=
COS	NVrzfHZQTnWwY4Tpc44h[XO\|YYm=				NF\ZSZpKdmirYnn0bY9vKG:oIHj1cYFvKEORWEGg[ZhxemW\|c3XkJIlvKGGocnnjZY4h\3KnZX6gcY9vc2W7IFPPV{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHyZYNpcWSxbnnjJIFkcWRvc4TpcZVt[XSnZDDQS2UzKHS{ZXH0[YQhOSCqcjDi[YZwemViYYLhZ4hq\G:waXOgZYNq\CClaHHscIVv\2ViYomg[Y57gW2nIHntcZVvd2G\|c3H5MEBKSzVyIE2gNU43QDlizszNMi=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV{MEW3N{c,OTl3MkC1O\|M9N2F-
RAW264.7	MnTlRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>?		MVKxPEBpenN?		NVPPVlZxSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIHHmeIVzKDF6IHjyd{BjgSCpcnnld5MhemWjY4Tpc44h[W6jbInzbZMtKEmFNUCgQUAyNjh2IN88UU4>	NUDkd\|U2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|k1PDFpPkK0Olc6PDRzPD;hQi=>
HCA-7	MlTBR5l1d3SxeHnjbZR6KGG\|c3H5		NGi2WngyQCCqcoO=		M3qz[2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhESS15IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxic4Xyeol3[WxiYX\0[ZIhOThiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDJizszNMi=>	M{K3PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUG3O\|IyLz5{M{WxO\|czOTxxYU6=
A549	M3v3RmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NGH4eW41QCCqcoO=		NE\JcodCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgbY5kfWKjdHXkJIZweiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMj6xOUDPxE1w	NHXWVWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO0OlM3Pyd-Mk[zOFY{Pjd:L3G+
Escherichia coli Arctic cells	NGTRSlhHfW6ldHnvckBie3OjeR?=		MWqxOUBucW6\|		MmDFTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDTeJJmeHSxY3;jZ5V{KG23dHHud{BWSTF3OTDi[ZRiNWOjcnLvcolkKGGwaInkdoF{\SCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDBdoN1cWNiY3XscJMheHKnaX7jeYJifGWmIH\vdkAyPSCvaX7zJIJ6KHO2b4Dw[YQh\myxdzDDU\|IhcHmmcnHz[UBie3OjeTygT4khRSB{LkSyOUDPxE1w	M4jmXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUGzNVk6Lz5{NUmxN\|E6QTxxYU6=
HT-29	M4PHXmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MkC4NVghcHK\|		NWXBTGo2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[2WubDDzeZJ3cX[jbDDh[pRmeiBzODDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMzFOwG0v	M2LYWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUG3O\|IyLz5{M{WxO\|czOTxxYU6=
J774	NVjiR49VTnWwY4Tpc44h[XO\|YYm=				MVXJcohq[mm2aX;uJI9nKEORWEGgbY4hdW:3c3WgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyCjcnHjbIlld26rYzDhZ4llNWmwZIXj[YQhWEeHMjDs[ZZmdHNiYomgdoFlcW9iaX3teY5w[XO\|YYmsJGlEPTBiPTCzMlch\|ryPLh?=	M1TqOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUG1PFU1Lz5zN{mxOVg2PDxxYU6=
J774	M2LFOmZ2dmO2aX;uJIF{e2G7		MVOxOUBucW6\|		NWXqUFZFUW6qaXLpeIlwdiCxZjDDU3gyKGmwIHHyZYNpcWSxbnnjJIFkcWRvc4TpcZVt[XSnZDDtc5V{\SCMN{e0JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiUFfFNkBxem:mdXP0bY9vKGGodHXyJFE2KG2rboOgZpkhemGmaX;pcY12dm:jc4PhfUwhUUN3MDC9JFMvPyEQvF2u	NXHSUIliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3OVI6PTdpPkG4O\|UzQTV5PD;hQi=>
J774	M4XDdWZ2dmO2aX;uJIF{e2G7		MmnyNVUhdWmwcx?=		M33zSGlvcGmkaYTpc44hd2ZiQ1;YMVEudWWmaXH0[YQhWEeHMjDwdo9lfWO2aX;uJIlvKGG{YXPobYRwdmmlIHHjbYQue3SrbYXsZZRm\CCvb4Xz[UBLPzd2IHPlcIx{KGmwY4XiZZRm\CCob4KgNVUhdWmwczDwdolweiC2bzDhdoFkcGmmb37pZ{Bi[2mmLXPoZYxt\W6pZTDifUBz[WSrb3ntcZVvd2G\|c3H5MEBKSzVyIE2gN{45PCEQvF2u	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl7MkG3Okc,OjF7OUKxO\|Y9N2F-
J774	NH3xdWhHfW6ldHnvckBie3OjeR?=		NYfLd2VPOTVibXnudy=>		M2riNGlvcGmkaYTpc44hd2ZiQ1;YNUBqdiCvb4Xz[UBLPzd2IHPlcIx{KHW\|aX7nJIFz[WOqaXTvcolkKGGlaXSgZZMhe3Wkc4TyZZRmKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhWEeHMjDwdo9lfWO2aX;uJIlv[3WkYYTl[EBnd3JiMUWgcYlveyCycnnvdkB1dyC\|dXLzeJJifGViYXTkbZRqd25ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BjgSC{YXTpc4ludXWwb3Hzd4F6NCCLQ{WwJF0hOy56NDFOwG0v	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6MES0OEc,OjN4OEC0OFQ9N2F-
APC10.1	NG\1[JpEgXSxdH;4bYNqfHliYYPzZZk>		NVznSlRsOThiaILz		MofyR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRXBEOTBwMTDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBk\WyuIIP1dpZqfmGuIHHmeIVzKDF6IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSB2LkKg{txONg>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzVzN{eyNUc,OjN3MUe3NlE9N2F-
B16F10	NWDlcHZDSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NXTIPWFqOjRiaILz		NXHtT5J[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCNVZHOTBiY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFQvPTZizszNMi=>	M2XxOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OE[2NlQxLz5{NUi2OlI1ODxxYU6=
HCA-7	NWLxSmJqS3m2b4TvfIlkcXS7IHHzd4F6				MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBEV1hvMjDwc5NqfGm4ZTDoeY1idiCKQ1GtO{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBjgSCFZXzsWIl1\XJvOU[gRXF2\W:3czDhd5NigSxiSVO1NEA:KDRwOTFOwG0v	M{HFVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm1O\|g4Lz5{NEK5OVc5PzxxYU6=
SH-SY5Y	M4PufmFvfGmwZYXyc5RwgGmlaYT5JIF{e2G7		MkXsO\|IhcHK\|		MVTBcpRqdmW3cn;0c5hq[2m2eTDpckBpfW2jbjDTTE1UYTW\IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gbJVu[W5iVFjQNUBk\WyuIIP1dIVzdmG2YX70MYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGOxbYDveY5lKHC{ZYTy[YF1\WRiMkSgeI8hPDhiaILzJJRwKFSKUEGgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhPzJiaILzJI9nKHO3cHXycoF1[W62IHHk[Il1cW:wLDDJR\|UxKD1iNTFOwG0v	NGjzTJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGzPFc4OCd-MkCxN\|g4PzB:L3G+
THP1	M1TCSW5mfXKxcILveIVkfGm4ZTDhd5NigQ>?		NIT5OIw4OiCqcoO=		MonTUoV2em:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiTGDTJIFv\CCLRl6t[4FudWFvc4TpcZVt[XSnZDDu[ZVzd3SxeHnuJJBzd2S3Y4Tpc44hcW5iaIXtZY4hXEiSMTDj[YxtKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhXEiSMTDj[YxtKHOnY4LleIlwdi2rbnT1Z4VlKHSxeHnjbZR6KHSxIHj1cYFvKFOKLWPZOXkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEWg{txONg>?	M1zEelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkC5OVg6Lz5{ME[wPVU5QTxxYU6=
U-937	MXvGeY5kfGmxbjDhd5NigQ>?				MlfETY5pcWKrdHnvckBw\iCScn;zeIFodGGwZHnuJGcwUCC\|eX70bIF{\SBzIHnuJHUuQTN5IHPlcIx{KG[{b32gbJVu[W5iaHnzeIlw[3m2aXOgcJlueGixbXGsJGlEPTBiPTC1MlEh\|ryPLh?=	NFiwWXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUS2Nlk4Pid-MUG0OlI6PzZ:L3G+
U-937	NWD2Z\|BtTnWwY4Tpc44h[XO\|YYm=				MVjJckB3cXS{bzDpcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUILvd5Ri\2yjbnTpckBIN0hic4nueIhie2ViMTCoR29ZNTFrIHnuJHUuQTN5IHPlcIx{NCCLQ{WwJF0hPS5zIN88UU4>	NUDXXIRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK4O\|c2QDRpPkGyPFc4PTh2PD;hQi=>
J774	MkG5SpVv[3Srb36gZZN{[Xl?				NHnqfmlKdiC4aYTyc{BqdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QhWHKxc4Th[4xidmSrbjDHM2ghe3mwdHjhd4UhOSCrbjDteZJqdmViSke3OEBk\WyuczygTWM2OCB;IEWuNUDPxE1w	MnrZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV6NUexOFkoRjF3OEW3NVQ6RC:jPh?=
J774	M2j3[2Z2dmO2aX;uJIF{e2G7				MXvJcohq[mm2aX;uJI9nKEORWEGt[IVx\W6mZX70JHBITTJicILv[JVkfGmxbjDpckBNWFNvc4TpcZVt[XSnZDDtc5V{\SCMN{e0JINmdGy\|IHL5JHJKSSxiSVO1NEA:KDVwMTFOwG0v	Mnm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7NUe5N\|EoRjF7OUW3PVMyRC:jPh?=
HT-29	NF7qTohEgXSxdH;4bYNqfHliYYPzZZk>				NHHGOYVEgXSxdH;4bYNqfHliYXfhbY5{fCCFT2itNkBxd3OrdHn2[UBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCkeTDD[YxtXGm2ZYKtPVYhSVG3ZX;1d{Bie3OjeTygTWM2OCB;IEWuO{DPxE1w	NVrHd3l6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVU4QDdpPkK0Nlk2Pzh5PD;hQi=>
MCF7	MV;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVKyOEBpenN?		NY\qN2lHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC1Mlk1KM7:TT6=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4NkK0NEc,OjV6Nk[yOFA9N2F-
APC10.1	NHPtPI5HfW6ldHnvckBie3OjeR?=		NIrp[3kyQCCqcoO=		M1H2cWlvcGmkaYTpc44hd2ZiaInhcJVzd26jbj3pcoR2[2WmIFPEOFQh[W62aXflckB3[XKrYX70JIV5d25iNjDhZ5Rqfmm2eTDpckBud3W\|ZTDBVGMyOC5zIHPlcIx{KGW6cILld5NqdmdiSHHzNkBie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKHO3co\peoFtKGGodHXyJFE5KGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUA3KM7:TT6=	NGTPVHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WxO\|czOSd-MkO1NVc4OjF:L3G+
MCF7	MnjVRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXi0PEBpenN?		M{HsNWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDpcoN2[mG2ZXSg[o9zKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB4Lki4JO69VS5?	NEPsT2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO0OlM3Pyd-Mk[zOFY{Pjd:L3G+
SW480	MmLmR5l1d3SxeHnjbZR6KGG\|c3H5				M2iyXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEORWD2yJI5m\2G2aY\lJIh2dWGwIGPXOFgxKGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGK7IFPlcIxVcXSncj25OkBCWXWnb4XzJIF{e2G7LDDJR\|UxKD1iNj65JO69VS5?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7NUe4O{c,OjR{OUW3PFc9N2F-
HeLa	NF3Ub2pCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MkHTNlQhcHK\|		MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEinTHGgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDdwM{Wg{txONg>?	NUfNSXI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlYzPDBpPkK1PFY3OjRyPD;hQi=>
HeLa	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NG\uZmw1QCCqcoO=		MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEinTHGgZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPy53NTFOwG0v	M{e1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{S2N\|Y4Lz5{NkO0OlM3PzxxYU6=
HeLa	M3;D[WFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MlS2NlQhcHK\|		NX7jWXNVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC3Mlc6KM7:TT6=	NXfwbnhQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezOFk{OzFpPkK3N\|Q6OzNzPD;hQi=>
HepG2	NH;LWYhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NX;WeJk{OjRiaILz		NEO0d5BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxNE4xOyEQvF2u	MoDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|NEmzN\|EoRjJ5M{S5N\|MyRC:jPh?=
APC10.1	NFf1N5BEgXSxdH;4bYNqfHliYYPzZZk>				MoqyR5l1d3SxeHnjbZR6KGGpYXnud5QhS0:[LUKgdI9{cXSrdnWgcY92e2ViQWDDNVAvOSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDIRXMuOiCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDifUBE\WyuVHn0[ZIuQTZiQWH1[Y92eyCjc4PhfUwhUUN3MDC9JFE{NjRizszNMi=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7NUe4O{c,OjR{OUW3PFc9N2F-
CHO	NUfWXWtCTnWwY4Tpc44h[XO\|YYm=				NWjLSZNiUW6qaXLpeIlwdiCxZjDDU3gyKGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhdoFkcGmmb37pZ{Bi[2mmLYP0bY12dGG2ZXSgVGdGOiCycn;keYN1cW:wIHL5JIVvgnmvZTDpcY12dm:jc4PhfUwhUUN3MDC9JFE{NjVizszNMi=>	NWLQSYtrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW1OlYzQTBpPkG1OVY3OjlyPD;hQi=>
B16F10	NHfaNIZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NFK4SFQzPCCqcoO=		NXjEOVBCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCNVZHOTBiY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFE1NjN4IN88UU4>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN2OUOzNUc,Ojd\|NEmzN\|E9N2F-
A549	NIfIcm5CdnSrdIXtc5Ih[XO\|YYm=		NWnudpNYPDhiaILz		M1f0UmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEG1MlYh\|ryPLh?=	NWjTUYZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOVM4PDFpPkKzN\|U{PzRzPD;hQi=>
A549	NHXSXpdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MVuyOEBpenN?		MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDF3Lk[0JO69VS5?	NVLneZJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezOFk{OzFpPkK3N\|Q6OzNzPD;hQi=>
HeLa	NYP1RYpMSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NXXEN\|dsPDhiaILz		NUH4UoxTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxOU43QSEQvF2u	M{XZdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEOxOlUzLz5\|MECzNVY2OjxxYU6=
A549	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M3PUfFQ5KGi{cx?=		NIT1UZJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEG2MlA5KM7:TT6=	M{\MZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEOxOlUzLz5\|MECzNVY2OjxxYU6=
NCI60	M4GwcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3y4fFQ5KGi{cx?=		MXjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2k3OCClZXzsd{Bi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NEA:KDF5LkWg{txONg>?	MnXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEe4NVUoRjJyM{i3PFE2RC:jPh?=
HCA-7	MWjGeY5kfGmxbjDhd5NigQ>?		MmW1NVghcHK\|		M{nYUWlvcGmkaYTpc44hd2ZiaInhcJVzd26jbj3pcoR2[2WmIFPEOFQh[W62aXflckB3[XKrYX70JIV5d25iNjDhZ5Rqfmm2eTDpckBpfW2jbjDIR2EuPyClZXzsd{BmgHC{ZYPzbY5oKEijc{KgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEB{fXK4aY\hcEBi\nSncjCxPEBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNVcvPSEQvF2u	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzVzN{eyNUc,OjN3MUe3NlE9N2F-
HT-29	M4rDRWZ2dmO2aX;uJIF{e2G7		Mn2wNVghcHK\|		M3nqbGlvcGmkaYTpc44hd2ZiaInhcJVzd26jbj3pcoR2[2WmIFPEOFQh[W62aXflckB3[XKrYX70JIV5d25iNjDhZ5Rqfmm2eTDpckBpfW2jbjDIWE0zQSClZXzsd{BmgHC{ZYPzbY5oKEijc{KgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEB{fXK4aY\hcEBi\nSncjCxPEBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNVgvOyEQvF2u	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzVzN{eyNUc,OjN3MUe3NlE9N2F-
platelet	NYfqNWZzTnWwY4Tpc44h[XO\|YYm=				M3jaVmlvcGmkaYTvdpkh\W[oZXP0JI9vKHC{b3T1Z5Rqd25ib3[gZ5lkdG:xeInn[Y5ie2VvMTCoR29ZNTFrIITodo9u[m:6YX7lJGIzKCiWWFKyLUBqdiCqdX3hckBxdGG2ZXzleEBk\WyuczygTWM2OCB;IEG5JO69VS5?	NXLvVnR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC4NlE4OTZpPkGwPFIyPzF4PD;hQi=>
B16F10	NWTxdXNPSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NXzzSHB[PDhiaILz		NFGwWIZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFKxOmYyOCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNVkvOTVizszNMi=>	NXnaN\|U3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|E3PTJpPkOwNFMyPjV{PD;hQi=>
MDA231	M{nleWFvfGmycn;sbYZmemG2aY\lJIF{e2G7				NFnRW5dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERVI{OSClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{Mj63PUDPxE1w	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJzNki0PEc,OzB{MU[4OFg9N2F-
MCF7	Mk[0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NULIco1XPDhiaILz		MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJ4Lke4JO69VS5?	NV;RTWNxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|E3PTJpPkOwNFMyPjV{PD;hQi=>
HCT116	NULJdXh{SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDifUBOXFRiYYPzZZktKEmFNUCgQUAzQS53NDFOwG0v	M1i5RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkG2PFQ5Lz5\|MEKxOlg1QDxxYU6=
MCF7	M1;0XGFvfGmycn;sbYZmemG2aY\lJIF{e2G7				Mo\hRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFMyNjJ6IN88UU4>	Mmn6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MU[4OFgoRjNyMkG2PFQ5RC:jPh?=
LNCAP	M333WGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M{e3eFczKGi{cx?=		NXPXc3JRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVE6FQWCgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOzJwNjFOwG0v	M3vEc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEW3OFA4Lz5{OEC1O\|QxPzxxYU6=
BL21(DE3)	M3jzT2Z2dmO2aX;uJIF{e2G7		NH7XN3QyPSCvaX7z		MojjTY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIF3hcIF{e2W8aXGg[4xw[m:\|YTDBWGNEKDl4OEC3M2NDWyB5OU[2JG1INUODIHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFqRFWzLUBk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEG1JI1qdnNibXXhd5Vz\WRiZn;yJFExKHSxIEGwNEB{\WNiYomgd5RweHCnZD3mcI94KG2ndHjv[EwhU2liPTCzOE45KM7:TT6=	NV;2N4tERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0NlQzOzlpPkKyOFI1OjN7PD;hQi=>
HeLa	MmOxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				NFTXO3NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOzZwMEig{txONg>?	NX\aemQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNVY5PDhpPkOwNlE3QDR6PD;hQi=>
MDA-MB-231	MnPXR5l1d3SxeHnjbZR6KGG\|c3H5		NIPpUWE1QCCqcoO=		MnixR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iNECg{txONg>?	MoX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5OEC5OlEoRjJ{N{iwPVYyRC:jPh?=
MCF7	Ml\wRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NGX0SY41QCCqcoO=		NInpZmhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBkd2yxcnnt[ZRzcWNiYYPzZZktKEmFNUCgQUA1OC56IN88UU4>	NUfTOWFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNFA6PDhpPkKyNFAxQTR6PD;hQi=>
MCF7	M1fjfGFvfGm2dX3vdkBie3OjeR?=		MXS0PEBpenN?		NFTjclJCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC0NE45KM7:TT6=	MkHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|NUO3OFEoRjJ\|M{WzO\|QyRC:jPh?=
Caco2	M4jvcGFvfGmycn;sbYZmemG2aY\lJIF{e2G7				M1XHZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ3Hjc\|Ih[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPDJwN{Sg{txONg>?	NWPn[nF4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNVY5PDhpPkOwNlE3QDR6PD;hQi=>
HCT116	MVHBcpRq[2GwY3XyJIF{e2G7		NUSyZ2NDPzJiaILz		M3jTdGFvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFQ{NjNizszNMi=>	MlzzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF4N{i5O\|EoRjJzNke4PVcyRC:jPh?=
L1210	MUHDfZRwfG:6aXPpeJkh[XO\|YYm=		NXrDS2FOPzJiaILz		M2X0XWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGwyOjFyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA1PCEQvF2u	MoLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2NUGzPVcoRjJyNEWxN\|k4RC:jPh?=
HT-29	NFWwUo9EgXSxdH;4bYNqfHliYYPzZZk>				NFLjZnFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC0OU42KM7:TT6=	NFyzZZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEiwOFE6Pyd-MkC4NFQyQTd:L3G+
PC3	MonHRY51cWOjbnPldkBie3OjeR?=				MWrBcpRq[2GwY3XyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy\|LDDHTVUxKD1iNEeg{txONg>?	NH2yS2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK2NlMxQSd-MUiyOlI{ODl:L3G+
PC3	NVvK[HVMSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2jsRlczKGi{cx?=		NH61cGtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIFv\HKxZ3XuMYlv\GWyZX7k[Y51KGi3bXHuJHBEOyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKHSnc4SsJGlEPTBiPTC0O{DPxE1w	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTV4NkK5NEc,OTV3Nk[yPVA9N2F-
PC3	MnTTRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3XHPVczKGi{cx?=		NXr5SZM6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IES4JO69VS5?	NFLicWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{mzO\|k4Oid-MUe5N\|c6PzJ:L3G+
PC3	NGn6eJBHfW6ldHnvckBie3OjeR?=		MYeyJIhzew>?		NHm1UVJKdmirYnn0bY9vKG:oIGDET\|EudWWmaXH0[YQhSWu2IHHjeIl3[XSrb36gbY4hcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEKgbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdiYX7hcJl{cXNuIFnDOVAhRSB2ODFOwG0v	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd\|NUK4NUc,OjN5M{WyPFE9N2F-
PC3	NH7mcplEgXSxdH;4bYNqfHliYYPzZZk>		MlTmO\|IhcHK\|		M1[4N2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gOFgvPSEQvF2u	NX;pe4Q3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OVE{QTdpPkKwOFUyOzl5PD;hQi=>
MCF7	M4fOWWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mly2O\|IhcHK\|		M{DnZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNEmuOlYh\|ryPLh?=	MkDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzOUG1NFIoRjJ7MUmxOVAzRC:jPh?=
A549	MnfLSpVv[3Srb36gZZN{[Xl?				Ml20TY5pcWKrdHnvckBw\iCFT2iyMYRmeGWwZHXueEBRT0V{IIDyc4R2[3Srb36gbY4hUUxzQjDzeIlufWyjdHXkJIh2dWGwIFG1OFkh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiYYLhZ4hq\G:waXOgZYNq\A>?	Mn33QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2OUixOVAoRjF6NEm4NVUxRC:jPh?=
A549	MknqSpVv[3Srb36gZZN{[Xl?				NHXLSm9KdmirYnn0bY9vKG:oIFPPXFIu\GWyZX7k[Y51KFCJRUKgdJJw\HWldHnvckBqdiCLTEHCJJN1cW23bHH0[YQhcHWvYX6gRVU1QSClZXzsdy=>	M3XzW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEm4NVUxLz5zOES5PFE2ODxxYU6=
A549	NWW5NW0{TnWwY4Tpc44h[XO\|YYm=	MoroOUB2VQ>?			MWPJcohq[mm2aX;uJI9nKG2SR1XTNUBqdiCqdX3hckBCPTR7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhUUxvMT3i[ZRiNWmwZIXj[YQhWEeHMjDmc5Ju[XSrb36gZZQhPSC3TTDifUBk\WyuLXnueIFkfCCjc4PhfS=>	M2jvU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEWzO\|UyLz5zOUC1N\|c2OTxxYU6=
A549	M2nzcWZ2dmO2aX;uJIF{e2G7	NFjl[Jc2KHWP	NGTtUYsyOCCvaX7z		NV\GeGdnUW6qaXLpeIlwdiCxZjDtVGdGWzFiaX6gTWwyNWKndHGgbY5lfWOnZDDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJHBITTJicILv[JVkfGmxbjDheEA2KHWPIIDy[Ylv[3WkYYTl[EBnd3JiMUCgcYlvew>?	NI\2fJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi4OFAyOSd-MUm4PFQxOTF:L3G+
PANC1	NEniZ4ZHfW6ldHnvckBie3OjeR?=	M{LqfVI2KHSxIEWwJG0>	M2DydVMxKG2rboO=		NYnoVIYxUW6qaXLpeIlwdiCxZjDJUE03NWmwZIXj[YQhW1SDVEOgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGDBUmMyKGOnbHzzJIF1KDJ3IITvJFUxKE1icILleJJm[XSnZDCyJIhzeyCycnnvdkB1dyCLTD22JINp[WyuZX7n[UBu\WG\|dYLl[EBi\nSncjCzNEBucW6\|	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ5OEm3NUc,OjF4N{i5O\|E9N2F-
HT29	NYjxTZVSTnWwY4Tpc44h[XO\|YYm=	MV:xNEB2VQ>?			Mly5TY5pcWKrdHnvckBw\iCqeXHseZJwdmGwLXnu[JVk\WRiQ1S0OEBidnSrZ3XuJJZiemmjboSg[ZhwdiB4IHHjeIl3cXS7IHnuJIh2dWGwIFjUNlkh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iNT3MU3gh\XiycnXzd4lwdiCjdDCxNEB2VQ>?	Mon4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUe3NlEoRjJ\|NUG3O\|IyRC:jPh?=
HT29	MX3GeY5kfGmxbjDhd5NigQ>?	M4fSWVExKHWP			MV3Jcohq[mm2aX;uJI9nKGi7YXz1do9v[W5vaX7keYNm\CCFRES0JIFvfGmpZX6geoFzcWGwdDDlfI9vKDZiYXP0bZZqfHliaX6gbJVu[W5iSGSyPUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCFT2itNkBmgHC{ZYPzbY9vKGG2IEGwJJVO	M2r0bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUG3O\|IyLz5{M{WxO\|czOTxxYU6=
HCA-7	NFfOSIVHfW6ldHnvckBie3OjeR?=	MkToOUB2VQ>?	NF3ROGQzPCCqcoO=		MmL3TY5pcWKrdHnvckBw\iCqeXHseZJwdmGwLXnu[JVk\WRiQ1S0OJY3KGmwIHj1cYFvKEiFQT23JINmdGy\|IITyZY5{\mWldHXkJJdqfGhiSHHzNoNFVkFiYYPz[ZN{\WRiYYOg[I94dnKnZ4XsZZRqd25ib3[gOU1NV1hicILveIVqdiCneIDy[ZN{cW:wIHH0JFUhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7NUe4O{c,OjR{OUW3PFc9N2F-
HCA-7	NGOwXnJHfW6ldHnvckBie3OjeR?=	NILtfok2KHWP	MYCyOEBpenN?		Ml[5TY5pcWKrdHnvckBw\iCqeXHseZJwdmGwLXnu[JVk\WRiQ1S0OJY3KGmwIHj1cYFvKEiFQT23JINmdGy\|IITyZY5{\mWldHXkJJdqfGhiSHHzNoNFVkFiYYPz[ZN{\WRiYYOg[I94dnKnZ4XsZZRqd25ib3[gR29ZNTJicILveIVqdiCneIDy[ZN{cW:wIHH0JFUhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM>	NXjITIVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVU4QDdpPkK0Nlk2Pzh5PD;hQi=>
HCA-7	NF;4T4VHfW6ldHnvckBie3OjeR?=	MXO1JJVO	NY\zVmxQOjRiaILz		M4TLO2lvcGmkaYTpc44hd2ZiaInhcJVzd26jbj3pcoR2[2WmIFPEOFR3PiCrbjDoeY1idiCKQ1GtO{Bk\WyuczD0doFve2[nY4Tl[EB4cXSqIFjhd\|JkTE6DIHHzd4V{e2WmIHHzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1zIIDyc5RmcW5iZYjwdoV{e2mxbjDheEA2KHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKGGwYXz5d4l{	M4TKb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm1O\|g4Lz5{NEK5OVc5PzxxYU6=
HeLa	NXjYNY9QTnWwY4Tpc44h[XO\|YYm=	MXuxNFAhfU1?	NEK4NpQzPCCqcoO=		NWHIbYs2UW6qaXLpeIlwdiCxZjDtVGdGWy1zIHnuJIh2dWGwIFjlUIEh[2WubIOgeZNqdmdiUFfINkBieyC\|dXLzeJJifGViYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCLTD2xZoV1[S:WTl\hcJBp[S2\|dHnteYxifGWmIGDHSVIheHKxZIXjeIlwdiCjdDCxNFAhfU1iYX\0[ZIhOjRiaILzJIJ6KEyFLV3TM21UKGGwYXz5d4l{	NV70O494RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxPFM4OzlpPkK0NVg{PzN7PD;hQi=>
HeLa	NFK0VWxHfW6ldHnvckBie3OjeR?=	MmK4NE4yKHWP	MofzNlQhcHK\|		Ml;OTY5pcWKrdHnvckBw\iCSR1WyJJNm[3KndHnvckBqdiCqdX3hckBJ\UyjIHPlcIx{KGG2IECuNUB2VSCjZoTldkAzPCCqcoOgZpkhTUmDIH3vco9kdG:wYXygZZN{[Xl?	MnrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|NEmzN\|EoRjJ5M{S5N\|MyRC:jPh?=
Saos-2	Ml;LdWhVWyCjc4PhfS=>				MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	M2r0VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RAW264.7	NFTvXGJCdnSraX7mcIFudWG2b4L5JIF{e2G7	NYnoVllJOjBidV2=	M1XHeFIhcHK\|		M4S1dWFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCUQWeyOlQvPyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWyCrbnT1Z4VlKGOxeD2yJIV5eHKnc4Ppc44h[XRiMkCgeW0heHKnaX7jeYJifGWmIH\vdkAzKGi{czDmc4xtd3enZDDifUBNWFNiY3jhcIxmdmenIH3lZZN2emWmIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgcYV1cG:m	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTFyMEe5PUc,OjlzMEC3PVk9N2F-
RAW264.7	NGTMcG9CdnSraX7mcIFudWG2b4L5JIF{e2G7	NVXzTXVIOjBidV2=	MWSyJIhzew>?		NY\aNotxSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIGLBW\|I3PC55IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhVFCVIHnu[JVk\WRiaV7PV{BmgHC{ZYPzbY9vKGG2IEKwJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhVFCVIHPoZYxt\W6pZTDt[YF{fXKnZDDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JI1mfGixZB?=	NYjXbo5YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxNFA4QTlpPkK5NVAxPzl7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Fibronectin / Vimentin / N-cadherin / E-cadherin ; PubMed: 28978083 Oncotarget (A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells. COX-2; PubMed: 29515134 Sci Rep L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. pAKT / AKT / PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h.	28978083 29515134 24721996
Immunofluorescence	PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.	24721996
Growth inhibition assay	Cell viability; PubMed: 28521485 Oncol Lett Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth.	28521485

In vivo

Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. ^[1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). ^[3]

Protocol

Kinase Assay:^[1]	- Collapse COX enzyme assay in vitro: Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:^[2]	- Collapse Cell lines: HNE1 and CNE1-LMP1 Concentrations: 0-75 μM Incubation Time: 48 hours Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats. Dosages: ≤200 mg/kg Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	76 mg/mL (199.28 mM)
	Ethanol	33 mg/mL (86.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Celecoxib SDF

Molecular Weight	381.37
Formula	C₁₇H₁₄F₃N₃O₂S
CAS No.	169590-42-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	SC 58635
Smiles	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04526197	Enrolling by invitation	Drug: ALXN1840\|Drug: Celecoxib	Wilson Disease	Alexion Pharmaceuticals	July 8 2020	Phase 1
NCT04447261	Recruiting	Drug: BI 1356225\|Drug: Placebo	Obesity	Boehringer Ingelheim	June 30 2020	Phase 1
NCT03896113	Recruiting	Drug: Celecoxib 200mg capsule	Endometrium Cancer	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	November 13 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?
Answer:
For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Pan COX inhibitor

Naproxen : Pan-COX inhibitor, COX-1, IC50=8.7 μM; COX-2, IC50=5.2 μM.
Most Potent COX Inhibitor

Lornoxicam : COX-1, IC50=5 nM; COX-2, IC50=8 nM.
FDA-approved COX Inhibitor

Ibuprofen : Approved by FDA for relieving pain, alleviating fever,and reducing inflammation.
Classic COX Inhibitor

Ketorolac : Non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Related COX Products

Xanthohumol ^New

Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Xanthohumol inhibits diacylglycerol acyltransferase 1 (DGAT1) and DGAT2 with both IC50 of 40 μM. Xanthohumol is also a potent antiviral agent against a series of DNA and RNA viruses. Xanthohumol induces growth inhibition and apoptosis in cancer cells. Phase 1.
AZD3839 ^New

AZD3839 is a potent and selective BACE1 inhibitor with K_i of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
A-438079 HCl ^New

A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
Indomethacin

Indomethacin (Indometacin) is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.
Lornoxicam

Lornoxicam (Chlortenoxicam) is a non-steroidal COX-1/COX-2 inhibitor, used as an anti-inflammatory drug to treat pain, osteoarthritis, and rheumatoid arthritis.
Aspirin

Aspirin (Acetylsalicylic acid, ASA) is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin induces autophagy and stimulates mitophagy.
Rofecoxib

Rofecoxib (MK-0966) is a COX-2 inhibitor with IC50 of 18 nM.
Ketorolac

Ketorolac is a non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).
Bufexamac

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.

Features:A specific inhibitor of class IIB histone deacetylases.
Ibuprofen

Ibuprofen (Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.

Features:Considered a core medicine in the WHO's "WHO Model List of Essential Medicines" (a list of the minimum medical requirements for a basic healthcare system).

Choose Your Country or Region

By Signaling Pathways

By product type

Celecoxib